Diversified Consumer Services
Company Overview of Rutgers, The State University of New Jersey
Rutgers, The State University of New Jersey is an educational institution that offers bachelors, masters, doctoral, and professional degrees. The institution provides courses in finance and accounting, sciences, engineering, computer science, social sciences, foreign languages, management, health sciences, and theater and visual arts. Rutgers, The State University of New Jersey was formerly known as Rutgers University and changed its name to Rutgers, The State University of New Jersey in January, 1945. The university was established in 1766 and is based in New Brunswick, New Jersey.
57 US Highway 1
New Brunswick, NJ 08901
Founded in 1766
Key Executives for Rutgers, The State University of New Jersey
Senior Vice President of Finance, Treasurer, and Chief Financial Officer
Executive Vice President of Academic Affairs
Executive Vice President of Development and Alumni Relations
Executive Editor and Senior Director of Media Relations
Compensation as of Fiscal Year 2015.
Rutgers, The State University of New Jersey Key Developments
Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ESS) for the Treatment of Severe Thermal Burn Wounds
Aug 3 15
Amarantus BioScience Holdings Inc. announced the signing of a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) and Rutgers, The State University of New Jersey (Rutgers University) to expand the development of Amarantus' autologous full thickness skin replacement product, Engineered Skin Substitute (ESS), for the treatment of deep partial- and full-thickness burn wounds in adult patients. Amarantus is developing ESS for the treatment of severe burns and is preparing to commence Phase 2 clinical studies in the third quarter of 2015. ESS has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of hospitalized patients with deep partial and full thickness burns requiring grafting, and has an open corporate-sponsored IND under which the clinical study can proceed.
Rutgers University and Professors Union Reach Tentative Deal to Raise Faculty Salary Minimums and Improve Family Leave Benefits
Feb 24 15
After months of tense contract negotiations, Rutgers University officials and representatives of its professors union have reached a tentative deal to raise faculty salary minimums and improve family leave benefits. But the two sides remain deadlocked on one big question: When can Rutgers freeze the salaries of its employees?. The American Association of University Professors-American Federation of Teachers, which represents Rutgers' professors and graduate students, is asking the university to change long-standing contract language that announces any negotiated raises are subject to 'adequate funding' from the state. Union officials announced the 'adequate funding' clause in the contract is too vague and allows Rutgers to freeze salaries on a whim by claiming the university does not have enough cash to cover raises. But Rutgers officials announced the clause is essential. Members of the faculty union are scheduled to hold a march and rally at 1:30 p.m. on February 24, 2015 to continue to pressure campus officials to finalize a deal. The march is scheduled to end with a protest inside Old Queens, the university's main administration building in New Brunswick. The two sides are also expected to hold a negotiating session February 24, 2015.
MYOS Corporation Establishes Research Relationship with Rutgers University in Muscle Science
Jun 24 14
MYOS Corporation announced that the company has entered into a three-year Master Service Agreement (MSA) with Rutgers, The State University of New Jersey, to engage Rutgers researchers in a program which will expand the MYOS' basic science platform for further development of Fortetropin(TM), the first clinically proven natural myostatin inhibitor, and other proprietary MYOS product formulations. The initial project with Rutgers will involve the development of cell-based assays for high throughput screening studies of next generation myostatin inhibitors such as peptides, proteins and small molecules. The program will be led by Joseph W. Freeman, Ph.D., Associate Professor, Department of Biomedical Engineering at Rutgers, and Principal Investigator along with his experienced team at the University's Musculoskeletal Tissue Regeneration Laboratory (MoTR). It is anticipated that the results of this program will allow MYOS to gain further insight into the mechanism of action of Fortetropin as it relates to myogenesis or the development of muscle tissue. MYOS expects the study to be completed mid-year 2015. In addition to the newly announced agreement with Rutgers, MYOS is a corporate sponsor of Rutgers Athletics. The company to support the University's sporting events, including the Scarlet Knights Football program, as it joins the prestigious Big Ten Conference this year. The Rutgers Athletics partnership with MYOS was a facilitated through IMG College Inc., the collegiate sports marketing company that represents Rutgers.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|